search
Back to results

Specialist Dietetic Intervention in Malnourished Patients With Fibrotic ILD: a Randomised Controlled Pilot Trial (DT-ILD)

Primary Purpose

Interstitial Lung Disease

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Dietetic intervention
Diet sheet (placebo)
Sponsored by
Royal Brompton & Harefield NHS Foundation Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Interstitial Lung Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: BMI ≤ 20kg/m2, or if aged >75, BMI ≤ 21 (Righini et al., 2013) Over the past 12 months, unintentional weight loss ≥ 5% of body weight, regardless of baseline BMI or weight loss >2 kg if BMI is normal. Exclusion Criteria: Co-morbidities currently requiring a specialised diet (including enteral feeding) End of life care (estimated less than 6 weeks left to live) Expected introduction of anti-fibrotic or immunosuppressive treatment or introduction/increase corticosteroid dose during trial period Pregnancy Unable to give consent

Sites / Locations

  • Royal Brompton HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Individualised dietetic advice

Diet sheet

Arm Description

Participants will receive 5 sessions receiving individualised nutritional counselling advice from a registered dietitian.

Participants will receive a diet sheet around poor appetite.

Outcomes

Primary Outcome Measures

Recruitment rate
Number individuals recruited/Number individuals contacted
Completion rate
Number individuals completing study/Number individuals randomised
Compliance
3 months

Secondary Outcome Measures

Nutritional status (Malnutrition)
PG-Subjective Global Assessment (SGA) which is a nutrition assessment tool using clinical parameters including weight loss, GI symptoms & functional capacity to diagnose malnutrition (Bauer et al., 2011).
Nutritional status (gastrointestinal related symptoms)
Gastrointestinal symptoms will be measured via the Gastrointestinal Symptom Rating Scale (GSRS) to further understand severity and impact of gastrointestinal related symptoms. (Svedlund et al., 1988)
Anthropometrics (weight)
Weight (kg) will be measured by VitaFit™ FCC/CE certified digital weighing scales provided during the first appointment or delivered at home, measured to an accuracy of 0.05kg. Dietitian led support for their use will be available.
Anthropometrics (height)
Height (m) will be derived from the most recent lung function reports.
Anthropometrics (Body Mass Index)
With the anthropometrics measured weight (kg) and height (m), this will be used to calculate Body Mass Index (BMI (kg/m2)).
Handgrip strength
Optimum nutrition can support maintenance of muscle to support activities of daily living. A CAMRY™ digital hand dynamometer will be delivered at home. HGS (kg) measures maximum voluntary muscle strength by squeezing the dynamometer providing a grip measurement accurate to 0.1kg.
Quality of Life (QoL)
Improved nutrition status may positively impact QoL. The King's Brief Interstitial Lung Disease Questionnaire (K-BILD), a 15-widely validated ILD-specific QoL questionnaire, will be used.
Energy and Protein intake
Participants will undertake a three-day diet diary at baseline and at 3 months to measure intake of macro and micronutrients will be calculated by using the software NutriticsTM, including daily total energy and protein intake as well as other nutrients, if necessary.

Full Information

First Posted
May 7, 2023
Last Updated
October 17, 2023
Sponsor
Royal Brompton & Harefield NHS Foundation Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT06016959
Brief Title
Specialist Dietetic Intervention in Malnourished Patients With Fibrotic ILD: a Randomised Controlled Pilot Trial
Acronym
DT-ILD
Official Title
Specialist Dietetic Intervention in Malnourished Patients With Fibrotic ILD: a Randomised Controlled Pilot Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 20, 2023 (Actual)
Primary Completion Date
January 28, 2024 (Anticipated)
Study Completion Date
March 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Royal Brompton & Harefield NHS Foundation Trust

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Malnutrition occurs when the body receives too few nutrients, resulting in health problems such as weight loss. The consequences of malnutrition are worrying as they include lung failure, infection, and pressure ulcers. Interstitial Lung Disease (ILD) is a term used for a group of diseases which can cause scarring of the lungs. Having ILD can cause malnutrition due to the lungs working hard and burning off energy. Additionally, medications called anti-fibrotic agents are used to slow disease progression. However, side effects include poor appetite, diarrhoea, nausea, vomiting and weight loss which can result in malnutrition. Malnutrition occurs in ILD in approximately half of patients. This is important because the main signs of malnutrition such as weight loss and a low Body Mass Index (BMI), which takes into consideration your weight against your height, are linked with worse outcomes in ILD. Malnutrition in ILD can also reduce eligibility for lung transplant and can impact tolerability of anti-fibrotic agents. Research into treatment of malnutrition in ILD is limited. Dietitians play a key role in diagnosis and treatment of malnutrition. This is because dietary counselling by a dietitian has been shown to increase quality of life and intake of energy in other chronic diseases. There are currently no studies documenting the benefits of dietetic intervention in patients with ILD. We propose to undertake the first feasibility study in this area. A feasibility study is a first step trial which investigates whether a study can & should be done. The main aims of this study are: How easy it is to recruit ILD patients to see a dietitian Whether patients will attend dietetic appointments Whether food/nutrient intake is increased following dietetic intervention How acceptable is dietetic intervention to ILD patients As well as these main aims, this study will also provide initial information about whether dietetic intervention stabilises weight, BMI & quality of life.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Interstitial Lung Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Individualised dietetic advice
Arm Type
Experimental
Arm Description
Participants will receive 5 sessions receiving individualised nutritional counselling advice from a registered dietitian.
Arm Title
Diet sheet
Arm Type
Placebo Comparator
Arm Description
Participants will receive a diet sheet around poor appetite.
Intervention Type
Other
Intervention Name(s)
Dietetic intervention
Intervention Description
Dietetic intervention involves individualised and tailored dietary advice to patients struggling with their nutrition. This includes optimising energy and protein intake to improve malnutrition & also giving dietary advice to support with nutrition impact symptoms e.g. bloating.
Intervention Type
Other
Intervention Name(s)
Diet sheet (placebo)
Intervention Description
Patients randomised into the group receiving a diet sheet will be sent out Royal Brompton & Harefield Hospital's Poor Appetite diet booklet which involves general strategies to improve nutritional status (energy and protein)
Primary Outcome Measure Information:
Title
Recruitment rate
Description
Number individuals recruited/Number individuals contacted
Time Frame
8 months
Title
Completion rate
Description
Number individuals completing study/Number individuals randomised
Time Frame
3 months
Title
Compliance
Description
3 months
Time Frame
Defined by increased energy & protein intake versus run-in (three-day diet-diaries).
Secondary Outcome Measure Information:
Title
Nutritional status (Malnutrition)
Description
PG-Subjective Global Assessment (SGA) which is a nutrition assessment tool using clinical parameters including weight loss, GI symptoms & functional capacity to diagnose malnutrition (Bauer et al., 2011).
Time Frame
3 months
Title
Nutritional status (gastrointestinal related symptoms)
Description
Gastrointestinal symptoms will be measured via the Gastrointestinal Symptom Rating Scale (GSRS) to further understand severity and impact of gastrointestinal related symptoms. (Svedlund et al., 1988)
Time Frame
3 months
Title
Anthropometrics (weight)
Description
Weight (kg) will be measured by VitaFit™ FCC/CE certified digital weighing scales provided during the first appointment or delivered at home, measured to an accuracy of 0.05kg. Dietitian led support for their use will be available.
Time Frame
3 months
Title
Anthropometrics (height)
Description
Height (m) will be derived from the most recent lung function reports.
Time Frame
3 months
Title
Anthropometrics (Body Mass Index)
Description
With the anthropometrics measured weight (kg) and height (m), this will be used to calculate Body Mass Index (BMI (kg/m2)).
Time Frame
3 months
Title
Handgrip strength
Description
Optimum nutrition can support maintenance of muscle to support activities of daily living. A CAMRY™ digital hand dynamometer will be delivered at home. HGS (kg) measures maximum voluntary muscle strength by squeezing the dynamometer providing a grip measurement accurate to 0.1kg.
Time Frame
3 months
Title
Quality of Life (QoL)
Description
Improved nutrition status may positively impact QoL. The King's Brief Interstitial Lung Disease Questionnaire (K-BILD), a 15-widely validated ILD-specific QoL questionnaire, will be used.
Time Frame
3 months
Title
Energy and Protein intake
Description
Participants will undertake a three-day diet diary at baseline and at 3 months to measure intake of macro and micronutrients will be calculated by using the software NutriticsTM, including daily total energy and protein intake as well as other nutrients, if necessary.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: BMI ≤ 20kg/m2, or if aged >75, BMI ≤ 21 (Righini et al., 2013) Over the past 12 months, unintentional weight loss ≥ 5% of body weight, regardless of baseline BMI or weight loss >2 kg if BMI is normal. Exclusion Criteria: Co-morbidities currently requiring a specialised diet (including enteral feeding) End of life care (estimated less than 6 weeks left to live) Expected introduction of anti-fibrotic or immunosuppressive treatment or introduction/increase corticosteroid dose during trial period Pregnancy Unable to give consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rasleen Kahai
Phone
020 7352 8121
Email
r.kahai@rbht.nhs.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Elisabetta Renzoni
Phone
020 7352 8121
Email
e.renzoni@rbht.nhs.uk
Facility Information:
Facility Name
Royal Brompton Hospital
City
London
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rasleen Kahai
Phone
02073528121
Ext
84454
Email
r.kahai@rbht.nhs.uk

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Specialist Dietetic Intervention in Malnourished Patients With Fibrotic ILD: a Randomised Controlled Pilot Trial

We'll reach out to this number within 24 hrs